You are viewing the site in preview mode
Skip to main content
| | |
All patient (n = 41)
|
With CIPN (n = 28)
|
Without CIPN (n = 13)
|
|---|
|
Age
| |
55.8 ± 11.0
|
57.0 ± 10.7
|
53.2 ± 11.6
|
|
Cancer type
|
Ovarian
|
22
|
16
|
6
|
|
Cervical
|
11
|
5
|
6
|
|
Endometrial
|
8
|
7
|
1
|
|
Regimen
|
TC ± BV
|
34
|
27
|
7
|
|
TP
|
5
|
1
|
4
|
|
PTX + NED
|
2
|
0
|
2
|
|
Cycle
| |
5.9 ± 0.4
|
5.9 ± 0.3
|
5.7 ± 0.7
|
|
Body-surface area (m2)
| |
1.484 ± 0.126
|
1.472 ± 0.121
|
1.509 ± 0.137
|
|
Cumulative PTX dose (mg/m2)
| |
1000.6 ± 101.3
|
1028.5 ± 38.6
|
940.8 ± 158.6
|
|
Cumulative Platinum dose (mg/m2)
|
CBDCA
|
2328.9 ± 305.5
|
2340.7 ± 294.5
|
2283.6 ± 366.7
|
|
CDDP
|
514.8 ± 112.4
|
296
|
331.8 ± 35.1
|
|
NED
|
604.0 ± 5.7
|
-
|
400
|
- Values are indicated as means ±standard deviations
-
PTX paclitaxel, CBDCA carboplatin, CDDP cisplatin, NED nedaplatin, TC ± BV bevacizumab (15 mg/kg) ± paclitaxel (175 mg/m2) + carboplatin (AUC = 6), TP paclitaxel (175 mg/m2) + cisplatin (75 mg/m2), PTX-NED paclitaxel (175 mg/m2) + nedaplatin (80 mg/m2)
